公开(公告)号：US09561311B2

公开(公告)日：2017-02-07

申请号：US14715282

申请日：2015-05-18

Applicant: CoDa Therapeutics, Inc.

Inventor： David Lawrence Becker ,  Colin Richard Green ,  Bradford James Duft

IPC: C07H21/04 ,  C07H21/02 ,  A61K39/395 ,  A61K48/00 ,  A61L31/16 ,  A61L17/00 ,  A61L27/54 ,  A61L31/08 ,  A61L31/10

CPC classification number: A61K38/08 ,  A61K9/0051 ,  A61K38/10 ,  A61K38/385 ,  A61L17/005 ,  A61L27/54 ,  A61L31/08 ,  A61L31/10 ,  A61L31/16 ,  A61L2300/25 ,  A61L2300/252 ,  A61L2300/258 ,  A61L2300/432 ,  A61L2300/602 ,  A61L2300/606 ,  A61L2300/608

Abstract: Medical devices comprising an anti-connexin agent suitable for introduction into a subject.

Abstract translation: 包括适合引入受试者的抗连接蛋白剂的医疗装置。

公开(公告)号：US20150297804A1

公开(公告)日：2015-10-22

申请号：US14715282

申请日：2015-05-18

Applicant: CoDa Therapeutics, Inc.

Inventor： David Lawrence BECKER ,  Colin Richard GREEN ,  Bradford James DUFT

IPC: A61L31/16 ,  A61L31/10 ,  A61L31/08

CPC classification number: A61K38/08 ,  A61K9/0051 ,  A61K38/10 ,  A61K38/385 ,  A61L17/005 ,  A61L27/54 ,  A61L31/08 ,  A61L31/10 ,  A61L31/16 ,  A61L2300/25 ,  A61L2300/252 ,  A61L2300/258 ,  A61L2300/432 ,  A61L2300/602 ,  A61L2300/606 ,  A61L2300/608

Abstract: Medical devices comprising an anti-connexin agent suitable for introduction into a subject.

Abstract translation: 包括适合引入受试者的抗连接蛋白剂的医疗装置。

公开(公告)号：US20140274872A1

公开(公告)日：2014-09-18

申请号：US13844553

申请日：2013-03-15

Applicant: CODA THERAPEUTICS, INC.

Inventor： BRADFORD J. DUFT ,  DAVID L. BECKER

IPC: A61K31/713 ,  A61K45/06 ,  A61K31/7088 ,  C07H21/00 ,  C07H21/02

CPC classification number: C12N15/113 ,  A61K31/7105 ,  A61K31/713 ,  A61K45/06 ,  C12N2310/111 ,  C12N2320/32 ,  A61K2300/00

Abstract: Anti-cadherin and anti-ZO-1 agents and compositions, and kits containing them for use in the promotion and/or improvement of wound healing and/or tissue repair, and for anti-scarring, anti-inflammatory, anti-fibrosis and anti-adhesion indications.

Abstract translation: 抗钙粘蛋白和抗ZO-1剂和组合物，以及含有它们的用于促进和/或改善伤口愈合和/或组织修复以及抗瘢痕形成，抗炎，抗纤维化和抗 粘附指示。

公开(公告)号：US20130079388A1

公开(公告)日：2013-03-28

申请号：US13681383

申请日：2012-11-19

Applicant: CODA THERAPEUTICS, INC.

Inventor： David Lawrence Becker ,  Colin Richard Green

IPC: C07H21/04

CPC classification number: C07H21/04 ,  A61K31/711 ,  A61K38/00 ,  C12N15/111 ,  C12N15/1138 ,  C12N2310/11 ,  C12N2320/32

Abstract: A therapeutic and/or cosmetic formulation comprising at least one anti-sense polynucleotide to a connexin protein together with a pharmaceutically acceptable carrier or vehicle is useful in site specific down regulation of connexin protein expression, particularly in reduction of neuronal cells death, wound healing, reduction of inflammation, decrease of scar formation and skin rejuvenation and thickening.

Abstract translation: 包含至少一种连接蛋白的反义多核苷酸与药学上可接受的载体或载体的治疗和/或化妆品制剂可用于连接蛋白表达的位点特异性下调，特别是在减少神经元细胞死亡，伤口愈合， 减少炎症，减少瘢痕形成和皮肤复原及增厚。

公开(公告)号：US20160264977A1

公开(公告)日：2016-09-15

申请号：US14777458

申请日：2014-03-15

Applicant: Bradford James DUFT ,  CODA THERAPEUTICS, INC.

Inventor： Anthony PHILLIPS ,  David EISENBUD ,  Scott BANNAN ,  David POOL ,  Grove MATSUOKA ,  Tracey SUNDERLAND ,  Bradford James DUFT

IPC: C12N15/113 ,  A61K47/10 ,  A61B5/00 ,  A61K47/38 ,  A61K31/7105 ,  A61K9/00 ,  A61K9/06

CPC classification number: A61K31/7088 ,  A61B5/0064 ,  A61B5/0077 ,  A61B5/1072 ,  A61B5/1079 ,  A61B5/1109 ,  A61B5/445 ,  A61B5/4839 ,  A61B5/4848 ,  A61B5/7275 ,  A61B2503/40 ,  A61K9/0014 ,  A61K9/06 ,  A61K9/70 ,  A61K31/7105 ,  A61K47/00 ,  A61K47/10 ,  A61K47/38 ,  A61K48/00 ,  C07K14/47 ,  C12N15/1138 ,  C12N2310/11 ,  C12N2310/14 ,  C12N2320/30 ,  C12N2320/35

Abstract: This invention concerns improved methods, uses, and kits for treating chronic wounds through the administration of anti-connexin agents, particularly anti-connexin 43 antisense polynucleotides. The methods, uses, and kits of the invention are based on the surprising and unexpected discovery that chronic wounds that do not increase or decrease in size by more than a pre-determined amount during a pre-treatment phase are more amenable to successful treatment than wounds whose size varies outside the target range during the pre-treatment phase.

Abstract translation: 本发明涉及通过施用抗连接蛋白剂，特别是抗连接蛋白43反义多核苷酸治疗慢性伤口的改进的方法，用途和试剂盒。 本发明的方法，用途和试剂盒基于惊人的和意想不到的发现，即在预处理阶段期间，不增加或减少大小超过预定量的慢性伤口比成功治疗更适合于比 在预处理阶段，其大小在目标范围之外变化的伤口。

公开(公告)号：US20160160214A1

公开(公告)日：2016-06-09

申请号：US14951424

申请日：2015-11-24

Applicant: CoDa Therapeutics, Inc.

Inventor： David Lawrence Becker ,  Colin Richard Green

IPC: C12N15/113

CPC classification number: C12N15/1138 ,  A61K9/0014 ,  A61K9/0019 ,  A61K9/06 ,  A61K31/711 ,  A61K47/34 ,  C12N2310/11 ,  C12N2320/32

Abstract: A therapeutic and/or cosmetic formulation comprising at least one anti-sense polynucleotide to a connexin protein together with a pharmaceutically acceptable carrier or vehicle is useful in site specific down regulation of connexin protein expression, particularly in reduction of neuronal cells death, wound healing, reduction of inflammation, decrease of scar formation and skin rejuvenation and thickening.

公开(公告)号：US20150218562A1

公开(公告)日：2015-08-06

申请号：US14396722

申请日：2013-04-23

Applicant: CoDa Therapeutics, Inc.

Inventor： Peter Cormie ,  David Becker ,  David Whitmore

IPC: C12N15/113

CPC classification number: C12N15/1137 ,  C12N15/113 ,  C12N2310/11

Abstract: The present invention concerns an isolated polynucleotide comprising a nucleotide sequence having substantial homology to any of the following nucleotide sequences: catcgttatgggacta (SEQ ID NO: 2), cattcttgatccttcc (SEQ ID NO: 1), cttttcaatctgactg SEQ ID NO: atgaaaatactcataa (SEQ ID NO: 5), gtgataaaagaaccat (SEQ ID NO: 10), gggttcatgaaagtga (SEQ ID NO: 11), gatgaccctcttatcc (SEQ ID NO: 8), tggaaggaatgtctgg (SEQ ID NO: 4), gcatctgcttccaaca (SEQ ID NO: 3), catcgttaggctagctacaacgatgggacta (SEQ ID NO: 9), tccaccaaggctagctacaacgaccatcaaa (SEQ ID NO: 12), gtcaacaaggctagctacaacgatgagctca (SEQ ID NO: 13), and cttttcaaggctagctacaacgactgactgt (SEQ ID NO: 6), and their use in the treatment of wounds.

Abstract translation: 本发明涉及一种分离的多核苷酸，其包含与以下任一核苷酸序列具有实质同源性的核苷酸序列：catcgttatgggacta（SEQ ID NO：2），cattcttgatccttcc（SEQ ID NO：1），cttttcaatctgactg SEQ ID NO：atgaaaatactcataa（SEQ ID NO ：SEQ ID NO：10），gggttcatgaaagtga（SEQ ID NO：10），gggttcatgaaagtga（SEQ ID NO：11），gatgaccctcttatcc（SEQ ID NO：8），tggaaggaatgtctgg（SEQ ID NO：4），gcatctgcttccaaca（SEQ ID NO：3），catcgttaggctagctacaacgatgggacta （SEQ ID NO：9），tccaccaaggctagctacaacgaccatcaaa（SEQ ID NO：12），gtcaacaaggctagctacaacgatgagctca（SEQ ID NO：13）和cttttcaaggctagctacaacgactgactgt（SEQ ID NO：6），以及它们在伤口治疗中的用途。

公开(公告)号：US10251929B2

公开(公告)日：2019-04-09

申请号：US15424758

申请日：2017-02-03

Applicant: CoDa Therapeutics, Inc.

Inventor： David Becker ,  Colin Green ,  Bradford Duft

IPC: C07H21/04 ,  C07H21/02 ,  A61K39/395 ,  A61K48/00 ,  A61K38/08 ,  A61L17/00 ,  A61L27/54 ,  A61L31/16 ,  A61L31/08 ,  A61L31/10 ,  A61K9/00 ,  A61K38/10 ,  A61K38/38

Abstract: Medical devices comprising an anti-connexin agent suitable for introduction into a subject.

公开(公告)号：US09937197B2

公开(公告)日：2018-04-10

申请号：US15076513

申请日：2016-03-21

Applicant: CoDa Therapeutics, Inc.

Inventor： Anthony Phillips ,  David Eisenbud ,  Scott Bannan ,  Grove Matsuoka ,  David Pool ,  Tracey Sunderland ,  Bradford Duft

IPC: C12N15/113 ,  A61K31/713 ,  A61K9/06 ,  A61K47/38 ,  A61K9/70 ,  A61K31/7088 ,  A61B5/107 ,  A61B5/11 ,  A61B5/00 ,  C07K14/47 ,  A61K47/00 ,  A61K9/00 ,  A61K48/00 ,  A61K31/7105 ,  A61K47/10

CPC classification number: A61K31/7088 ,  A61B5/0064 ,  A61B5/0077 ,  A61B5/1072 ,  A61B5/1079 ,  A61B5/1109 ,  A61B5/445 ,  A61B5/4839 ,  A61B5/4848 ,  A61B5/7275 ,  A61B2503/40 ,  A61K9/0014 ,  A61K9/06 ,  A61K9/70 ,  A61K31/7105 ,  A61K47/00 ,  A61K47/10 ,  A61K47/38 ,  A61K48/00 ,  C07K14/47 ,  C12N15/1138 ,  C12N2310/11 ,  C12N2310/14 ,  C12N2320/30 ,  C12N2320/35

Abstract: This invention concerns improved methods, uses, and kits for treating chronic wounds through the administration of anti-connexin agents, particularly anti-connexin 43 antisense polynucleotides. The methods, uses, and kits of the invention are based on the surprising and unexpected discovery that chronic wounds that do not increase or decrease in size by more than a pre-determined amount during a pre-treatment phase are more amenable to successful treatment than wounds whose size varies outside the target range during the pre-treatment phase.

公开(公告)号：US20170056468A1

公开(公告)日：2017-03-02

申请号：US15247853

申请日：2016-08-25

Applicant: CoDa Therapeutics, Inc.

Inventor： David EISENBUD ,  Anthony PHILLIPS ,  Scott BANNAN ,  Grove MATSUOKA ,  DUFT Bradford

IPC: A61K38/17 ,  A61K9/06 ,  A61K47/10 ,  C12N15/113

CPC classification number: A61K38/177 ,  A61K9/0014 ,  A61K9/06 ,  A61K47/10 ,  C12N15/1138 ,  C12N2310/11 ,  C12N2320/30

Abstract: Connexin protein modulation methods and compositions are provided for the healing of resistant lesions, including lesions on subjects with multiple venous leg ulcers or multiple diabetic foot ulcers, and other responder subjects. Also provided are kits and articles of manufacture comprising a connexin protein modulating agent, for example, a connexin 43 modulating agent for use in the healing of resistant lesions.

Abstract translation: 提供连接蛋白调节方法和组合物用于治疗耐药性病变，包括具有多个静脉性腿部溃疡或多发性糖尿病足溃疡的受试者的损伤以及其他应答者受试者。 还提供了包含连接蛋白调节剂的试剂盒和制品，例如用于治疗耐药损伤的连接蛋白43调节剂。